What to Do Next: Sequencing of Therapy in Patients With Metastatic CRC

Slides:

Advertisements

Similar presentations

Post G.I. ASCO Update: Colorectal Cancer Ronald Burkes, M.D.

Advertisements

What should patients with BRAF mutant melanoma receive as front line therapy? Antoni Ribas, M.D. Professor of Medicine Professor of Surgery Professor of.

Presented By Alan Venook at 2016 ASCO Annual Meeting

Upfront Combination Therapy vs Step-Up Approach for PAH:

Prognostic Factors for First-line Chemotherapy + Bevacizumab or Cetuximab in Metastatic Colorectal Cancer CCO Independent Conference Highlights* of the.

CCO Independent Conference Highlights

Presented By Michael Lee at 2016 ASCO Annual Meeting

Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.

How attached did you feel to this patient emotionally?

Introduction. TREATMENT BASED ON TUMOR SIDEDNESS IN mCRC: THE EVIDENCE AND PRACTICAL APPLICATION.

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

Challenges in RAS Wild-Type mCRC

New ESMO Guidance on Tumor Sidedness in mCRC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

A Paradigm Shift From One-Size-Fits-All to Tailor-Made Therapy for Metastatic Colorectal Cancer.

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: A Clinical Update

State of the Art in HCC: Immune Checkpoint Modulation

The Nurse View.

New Patient Journeys in Non-small cell lung cancer

Introduction. TREATMENT BASED ON TUMOR SIDEDNESS IN mCRC: THE EVIDENCE AND PRACTICAL APPLICATION.

Metastatic Renal Cell Carcinoma

Colorectal Cancer: Current “Standard” Uses for Molecular Testing

Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?

Optimizing Outcomes in the Management of GIST

Introduction. For Pulmonologists by Pulmonologists: Diagnosis of NSCLC in an Age of Biomarkers.

Program Goals Introduction Case 1: A 44-Year-Old Woman.

Chronic Idiopathic Urticaria

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

T790M Mutation-Positive NSCLC: A Multidisciplinary Case Conference

Liquid Biopsy for RAS Screening in CRC: How Can We Successfully Implement This New Paradigm?

CDK4/6 Inhibitors in Practice

EGFR Inhibitors in Advanced NSCLC: Who, When, and Why?

Best Practices in Metastatic Colorectal Cancer

Managing gBRCA-Positive Metastatic Breast Cancer

Braf-MUTATION POSITIVE melanoma: a case conference

Immunotherapy for cSCC

Emerging Frontline Treatments for Patients With Hodgkin Lymphoma

Advancing Care in Genitourinary Cancer: Perspectives From Chicago

Personalized Therapy in Relapsed or Refractory CLL

Locally Advanced Lung Cancer

The Role of IDH Inhibitors in Hematologic Malignancies

Patient-Centered Management in BRAF-Positive Metastatic Melanoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Progress of the NSCLC Revolution

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

The Changing Field of Melanoma: Ipilimumab.

Challenges in LA SCCHN.

Novel Concepts in the Management of RCC

From Adjuvant to Metastatic in Melanoma

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

New Insights on Treatment Strategies for mCRC:

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

Ali Shamseddine,MD,FRCP

Checkpoint Inhibitors in First-Line Advanced NSCLC

CRC-TREATMENT BEYOND SECOND LINE

The Nurse View: Spotlight on EGFR-Mutated NSCLC

Investigator Perspectives on the Current Utility of Validated and Emerging Biomarkers to Guide Treatment Decision-Making for Patients with Metastatic Colorectal.

Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.

Evaluating the Totality of Evidence

Current Status of Biomarkers for Immune Checkpoint Inhibitors

Clinical Focus.

The Nurse View.

Targeting Glioblastoma: EGFR and Novel Approaches to Therapy

Recent Developments in the Treatment of Advanced and Metastatic RCC

Updates in Best Practices in Non-Small Cell Lung Cancer

Consort diagram of the study depicting the process of patients’ selection. Consort diagram of the study depicting the process of patients’ selection. A.

Presentation transcript:

What to Do Next: Sequencing of Therapy in Patients With Metastatic CRC

Sequencing Therapy in mCRC Introduction

Case Study

Role of Maintenance Therapy

Second-Line Therapy in mCRC

Second-Line mCRC Anti-EGFR Therapy

Role of Tumor Sidedness

CALGB/SWOG 80405: Effect of Primary Tumor Location on OS and PFS

Case Study (cont)

RECOURSE Phase 3 Trial TAS-102 for Refractory mCRC

CORRECT Trial Regorafenib Monotherapy for mCRC

Regorafenib Dosing

MCRC BRAF V600E Mutant Right-Sided Tumors

SWOG 1406: Vemurafenib in mCRC BRAF Inhibitor

BRAF V600E Mutant mCRC Ongoing Clinical Trials

Non-V600E Mutated Tumors

Microsatellite Instability Status

Ongoing Clinical Trials in dMMR or MSI-High CRC

Phase 1 Cobimetinib + Atezolizumab in Unresectable mCRC

Concluding Remarks

Abbreviations

Abbreviations (cont)